These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 33008345

  • 1. Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study.
    Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H.
    BMC Psychiatry; 2020 Oct 02; 20(1):485. PubMed ID: 33008345
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B.
    Eur Neuropsychopharmacol; 2014 Dec 02; 24(12):1861-72. PubMed ID: 25453486
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of guanfacine extended-release in Japanese adults with attention-deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study.
    Naya N, Sakai C, Okutsu D, Kiguchi R, Fujiwara M, Tsuji T, Iwanami A.
    Neuropsychopharmacol Rep; 2021 Mar 02; 41(1):26-39. PubMed ID: 33305542
    [Abstract] [Full Text] [Related]

  • 7. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, Lyne A, Grannis K, Youcha S.
    J Am Acad Child Adolesc Psychiatry; 2012 Jan 02; 51(1):74-85.e2. PubMed ID: 22176941
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder.
    Sallee FR, Kollins SH, Wigal TL.
    J Child Adolesc Psychopharmacol; 2012 Jun 02; 22(3):206-14. PubMed ID: 22612526
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.
    Buitelaar JK, Casas M, Philipsen A, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, van Oene JC, Schäuble B.
    Psychol Med; 2012 Jan 02; 42(1):195-204. PubMed ID: 21733214
    [Abstract] [Full Text] [Related]

  • 17. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A, Hull JT, Chaturvedi SA, Liranso T, Odebo O, Kosheleff AR, Fry N, Cutler AJ, Rubin J, Schwabe S, Childress A.
    CNS Drugs; 2022 Aug 02; 36(8):897-915. PubMed ID: 35896943
    [Abstract] [Full Text] [Related]

  • 18. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Faraone SV, McBurnett K, Sallee FR, Steeber J, López FA.
    Clin Ther; 2013 Nov 02; 35(11):1778-93. PubMed ID: 24139092
    [Abstract] [Full Text] [Related]

  • 19. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S.
    CNS Drugs; 2017 Nov 02; 31(11):999-1014. PubMed ID: 28980198
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.
    Pharmacoeconomics; 2012 Aug 01; 30(8):e1-15. PubMed ID: 22788263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.